DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

  • RESET FILTERS

    Immune Checkpoint Inhibitors: EU Access & Reimbursement

    Immune checkpoint inhibitors, including Bristol-Myers Squibb’s Opdivo and Yervoy, and Merck & Co.’s Keytruda, are revolutionizing the therapeutic strategies of several cancers, notably malignant melanoma, non-small-cell lung cancer (NSCLC) and renal cell carcinoma (RCC). In Europe, Opdivo plus Yervoy is the first immune checkpoint inhibitor regimen to get approval for malignant melanoma, and, in 2017, the European Commission granted a label expansion to Keytruda for first-line treatment of PD-L1-positive metastatic NSCLC. As these premium-priced therapies enter novel indications and patient populations, payer-imposed reimbursement restrictions and cost-containment strategies will continue to play an increasingly pivotal role in oncologists’ drug selection and prescribing practices, and, in turn, the commercial success of immune checkpoint inhibitors.

     

    QUESTIONS ANSWERED

    • What are the key driving forces and constraints that influence EU5 payers’ reimbursement decisions for immune checkpoint inhibitors in malignant melanoma, NSCLC, and RCC?
    • How do market access and reimbursement policies at national, regional, and local level shape prescribing preferences for immune checkpoint inhibitors? How do payers prioritize diminishing budgets, and monitor prescribing of immune checkpoint inhibitors accordingly?
    • How to oncologists view select emerging immune checkpoint inhibitors and do they expect to prescribe them? To what extent will EU5 payer policy likely impact uptake of these novel agents?

     

    PRODUCT DESCRIPTION

    Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.